surpass 5 tirzepatide Changes in HbA1c from baseline to end of treatment in 1-5 [10-14] New research from the SURPASS-EARLY

For patients whose primary goal is fat loss and body composition improvement: Ipamorelin may be preferred due to its selective GH stimulation without cortisol elevation Cortisol is directly antagonistic to fat loss, particularly visceral fat The clean GH pulse from ipamorelin supports lipolysis without metabolic interference Sermorelin also supports fat metabolism through sustained GH improvement The best approach depends on individual factors including baseline hormone levels, cortisol status, and treatment goals

Novo leadership pointed to the open-label design as a source of bias, suggesting that investigators, many of whom were already familiar and comfortable with Tirzepatide, may have pushed patients more aggressively on the Lilly arm

The study was some of the first evidence that the hormone had an effect in the brain

Read our companion piece on the Lee and Burgess IV pilot for the full study breakdown